Your browser doesn't support javascript.
loading
Progression of regional grey matter atrophy in multiple sclerosis.
Eshaghi, Arman; Marinescu, Razvan V; Young, Alexandra L; Firth, Nicholas C; Prados, Ferran; Jorge Cardoso, M; Tur, Carmen; De Angelis, Floriana; Cawley, Niamh; Brownlee, Wallace J; De Stefano, Nicola; Laura Stromillo, M; Battaglini, Marco; Ruggieri, Serena; Gasperini, Claudio; Filippi, Massimo; Rocca, Maria A; Rovira, Alex; Sastre-Garriga, Jaume; Geurts, Jeroen J G; Vrenken, Hugo; Wottschel, Viktor; Leurs, Cyra E; Uitdehaag, Bernard; Pirpamer, Lukas; Enzinger, Christian; Ourselin, Sebastien; Gandini Wheeler-Kingshott, Claudia A; Chard, Declan; Thompson, Alan J; Barkhof, Frederik; Alexander, Daniel C; Ciccarelli, Olga.
Afiliação
  • Eshaghi A; Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Marinescu RV; Centre for Medical Image Computing (CMIC), Department of Computer Science, University College London, UK.
  • Young AL; Centre for Medical Image Computing (CMIC), Department of Computer Science, University College London, UK.
  • Firth NC; Centre for Medical Image Computing (CMIC), Department of Computer Science, University College London, UK.
  • Prados F; Centre for Medical Image Computing (CMIC), Department of Computer Science, University College London, UK.
  • Jorge Cardoso M; Translational Imaging Group, Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, UK.
  • Tur C; Translational Imaging Group, Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, UK.
  • De Angelis F; Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Cawley N; Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Brownlee WJ; Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • De Stefano N; Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Laura Stromillo M; Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
  • Battaglini M; Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
  • Ruggieri S; Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
  • Gasperini C; Department of Neurosciences, S Camillo Forlanini Hospital, Rome, Italy.
  • Filippi M; Department of Neurology and Psychiatry, University of Rome Sapienza, Rome, Italy.
  • Rocca MA; Department of Neurosciences, S Camillo Forlanini Hospital, Rome, Italy.
  • Rovira A; Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
  • Sastre-Garriga J; Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
  • Geurts JJG; MR Unit and Section of Neuroradiology, Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Vrenken H; Department of Neurology/Neuroimmunology, Multiple Sclerosis Centre of Catalonia (CEMCAT), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Wottschel V; Department of Anatomy and Neurosciences, VUmc MS Center, Neuroscience Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
  • Leurs CE; Department of Radiology and Nuclear Medicine, MS Center Amsterdam, Amsterdam, The Netherlands.
  • Uitdehaag B; Department of Radiology and Nuclear Medicine, MS Center Amsterdam, Amsterdam, The Netherlands.
  • Pirpamer L; Department of Neurology, MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
  • Enzinger C; Department of Neurology, MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
  • Ourselin S; Department of Neurology, Medical University of Graz, Graz, Austria.
  • Gandini Wheeler-Kingshott CA; Department of Neurology, Medical University of Graz, Graz, Austria.
  • Chard D; Division of Neuroradiology, Department of Radiology, Medical University of Graz, Graz, Austria.
  • Thompson AJ; Translational Imaging Group, Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, UK.
  • Barkhof F; National Institute for Health Research (NIHR), University College London Hospitals (UCLH) Biomedical Research Centre (BRC), London, UK.
  • Alexander DC; Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Ciccarelli O; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Brain ; 141(6): 1665-1677, 2018 06 01.
Article em En | MEDLINE | ID: mdl-29741648
ABSTRACT
See Stankoff and Louapre (doi10.1093/brain/awy114) for a scientific commentary on this article.Grey matter atrophy is present from the earliest stages of multiple sclerosis, but its temporal ordering is poorly understood. We aimed to determine the sequence in which grey matter regions become atrophic in multiple sclerosis and its association with disability accumulation. In this longitudinal study, we included 1417

subjects:

253 with clinically isolated syndrome, 708 with relapsing-remitting multiple sclerosis, 128 with secondary-progressive multiple sclerosis, 125 with primary-progressive multiple sclerosis, and 203 healthy control subjects from seven European centres. Subjects underwent repeated MRI (total number of scans 3604); the mean follow-up for patients was 2.41 years (standard deviation = 1.97). Disability was scored using the Expanded Disability Status Scale. We calculated the volume of brain grey matter regions and brainstem using an unbiased within-subject template and used an established data-driven event-based model to determine the sequence of occurrence of atrophy and its uncertainty. We assigned each subject to a specific event-based model stage, based on the number of their atrophic regions. Linear mixed-effects models were used to explore associations between the rate of increase in event-based model stages, and T2 lesion load, disease-modifying treatments, comorbidity, disease duration and disability accumulation. The first regions to become atrophic in patients with clinically isolated syndrome and relapse-onset multiple sclerosis were the posterior cingulate cortex and precuneus, followed by the middle cingulate cortex, brainstem and thalamus. A similar sequence of atrophy was detected in primary-progressive multiple sclerosis with the involvement of the thalamus, cuneus, precuneus, and pallidum, followed by the brainstem and posterior cingulate cortex. The cerebellum, caudate and putamen showed early atrophy in relapse-onset multiple sclerosis and late atrophy in primary-progressive multiple sclerosis. Patients with secondary-progressive multiple sclerosis showed the highest event-based model stage (the highest number of atrophic regions, P < 0.001) at the study entry. All multiple sclerosis phenotypes, but clinically isolated syndrome, showed a faster rate of increase in the event-based model stage than healthy controls. T2 lesion load and disease duration in all patients were associated with increased event-based model stage, but no effects of disease-modifying treatments and comorbidity on event-based model stage were observed. The annualized rate of event-based model stage was associated with the disability accumulation in relapsing-remitting multiple sclerosis, independent of disease duration (P < 0.0001). The data-driven staging of atrophy progression in a large multiple sclerosis sample demonstrates that grey matter atrophy spreads to involve more regions over time. The sequence in which regions become atrophic is reasonably consistent across multiple sclerosis phenotypes. The spread of atrophy was associated with disease duration and with disability accumulation over time in relapsing-remitting multiple sclerosis.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Encéfalo / Progressão da Doença / Substância Cinzenta / Esclerose Múltipla Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Brain Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Encéfalo / Progressão da Doença / Substância Cinzenta / Esclerose Múltipla Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Brain Ano de publicação: 2018 Tipo de documento: Article